

October 23, 2025

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001
BSE Scrip Code: 524743

To

National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor
Plot No. C/ 1, G Block,
Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051
NSE Symbol: FISCHER

Dear Sir,

Reg : Press Release: Nanomedic Clears UK NHS Hurdle, Launches India Market Strategy, and Targets US FDA Submission

We enclose a press release regarding **"Nanomedic Clears UK NHS Hurdle, Launches India Market Strategy, and Targets US FDA Submission"**, for dissemination.

Thanking you,
Yours Truly,
For **FISCHER MEDICAL VENTURES LIMITED**



ARAVINDKUMAR V
COMPANY SECRETARY & COMPLIANCE OFFICER





CIN L86900AP1993PLC118162

Corporate Office : Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006
Registered Office : No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032

Fischer Medical Ventures: Nanomedic Clears UK NHS Hurdle, Launches India Market Strategy, and Targets US FDA Submission

CHENNAI, INDIA / TEL AVIV, ISRAEL – October 23, 2025 – Fischer Medical Ventures Ltd. (FMVL), today announced major milestones achieved by its portfolio company, Nanomedic Technologies Ltd. The achievements include the successful registration of Nanomedic's flagship product, **SpinCare®**, with the UK's National Health Service (NHS), significant global market expansion, and strategic preparations for a large-scale launch in the Indian market.

UK Breakthrough: NHS Approval and London Hospital Partnership

Nanomedic has successfully completed the registration of its innovative **SpinCare®** solution with the **NHS** for the UK market, a key regulatory achievement that opens the door to one of the world's most influential healthcare systems. The company has already commenced collaboration with one of London's largest hospitals to establish its presence. With the addition of the UK, Nanomedic's advanced wound care solution is now approved for sale in **34 countries** across Europe, South America, and Asia.

Strategic Preparation for High-Impact India Market Entry - Progress of Device Registration for SpinCare® in India

Nanomedic is steadily advancing its expansion into the Indian market, marked by the completion of all necessary documentation for the registration of its SpinCare® device in India. The company has already secured a license from the Central Drug Standard Control Organization (**CDSCO**), authorising the import of SpinCare® for the purposes of clinical investigations, trials, tests and evaluations, as well as for demonstration and training activities.

In addition, Nanomedic has finalised the process for obtaining the MD 15 licence from **CDSCO**, which is required for importing SpinCare® for commercial use within India. The application for the MD 15 licence has been duly submitted and is currently pending final approval from the CDSCO authorities.

Anticipating this key regulatory milestone, Nanomedic has proactively engaged with major Indian hospitals specializing in **burn injury treatment and chronic wound management**, including potential tie-ups with government hospitals. Trials have recently commenced under a non-commercial framework. SpinCare® stands out as a **unique offering in the Indian market**, with no direct like-to-like competitors, and these strategic efforts aim to establish optimized treatment protocols that significantly reduce the overall treatment burden, improve patient quality of life, and deliver demonstrably rapid healing nationwide.



Operational and Regulatory Reinforcement

Nanomedic is reinforcing its structure to support this global expansion. The company successfully completed Phase One of its **MDR/MDD** (Medical Device Regulation/Medical Device Directive) audits for the renewal of its CE certification and is scheduled to complete Phase Two by **October 15, 2025**.

Furthermore, the leadership team has been strengthened with key hires, including a **Head of Operations**, a **Head of Business Development and Sales**, and a **VP of Clinical and North American Regulatory Affairs**. The new VP, with a strong history of successful FDA submissions, is preparing SpinCare®'s next FDA filing with the CTO and US regulatory consultants. The process is already underway, with an FDA outcome meeting expected in Q4 2025

Compelling Clinical Validation for SpinCare®

The strong clinical foundation of SpinCare® continues to expand, validated by peer-reviewed evidence over the past year:

A **Burns retrospective cohort** confirmed the safe and feasible use of SpinCare® in **pediatric burns**.

A **Randomized JEADV Clinical Practice pilot** published by **Stanford University** showed good tolerability and no device-related adverse events (AEs) with closure comparable to the control in patients with epidermolysis bullosa.

A **Bioengineering** **real-world evaluation** reported significantly greater **pain relief**, faster progression to **epithelialization**, **fewer rehospitalizations**, and **higher patient satisfaction**.



"These milestones at Nanomedic are a clear validation of our investment strategy and the transformative potential of their SpinCare® technology," said Mr. Ravindran Govindan, MD and Chairman of Fischer Medical Ventures Limited. "The NHS registration solidifies a major European market, while the proactive steps taken in India—particularly the hospital collaborations—demonstrate a sharp focus on impactful, localized market strategy. Fischer Medical Ventures looks forward to supporting Nanomedic as it transitions from an innovative medtech company to a global leader in advanced wound care."



About Fischer Medical Ventures Ltd. (FMVL)

Fischer Medical Ventures Limited (FMV) is driving a global shift in healthcare through innovative, cost-effective medical imaging and advanced diagnostics. Beyond medical devices, FMV offers a wide range of point-of-care diagnostic solutions, enabling timely and accurate patient care. Leveraging expertise, resources, and strategic partnerships, the company is committed to enhancing accessibility, affordability, and progress in healthcare delivery, creating a meaningful impact on healthcare systems worldwide.

About Nanomedic Technologies Ltd.

Nanomedic Technologies Ltd. is a medical device company specializing in advanced wound care. Its flagship product, SpinCare®, uses portable electrospinning technology to create an advanced, temporary skin substitute that provides a protective barrier for various wound types, promoting a clean, controlled healing environment.

For further information, please contact:

Fischer Medical Ventures Limited

Email: enquiry@fischermv.com

Website: www.fischermv.com

Contact: **9080966548**

Disclaimer:

This investor release is not an offer to sell any securities or a solicitation to buy any securities of Fischer Medical Ventures Limited (the "company") or its subsidiaries (together with the company, the "group"). Certain statements in this document may be forward looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "or" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intention. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements.

Forward looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved.

The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Investor Release, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. **FISCHERMVL** will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.
